FDA ends GLP-1 compounding for semaglutide, tirzepatide
Update: 2025-06-03
Description
FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide.
Featuring: Sara Heath, executive editor, Xtelligent Healthcare
Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent Healthcare
In today’s episode, we’ll cover…
- The end of GLP-1 compounding creates a significant access barrier for millions of patients seeking weight management solutions
- Financial inequity deepens as patients transition from affordable compounded options to expensive branded medications
- Future innovation in oral GLP-1 formulations offers hope but remains constrained by long-term patent protections
and more!
References:
- Anticipating the healthcare reach of GLP-1 receptor agonists
- Are compounded GLP-1 drugs safe?
- FDA winds down GLP-1 compounding policies
To learn more about GLP-1s, check out our Pharma Life Sciences and Patient Engagement sites.
To watch the video clips of our podcast, subscribe to our YouTube channel, @HealthcareStrategies.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
